Compare Citigroup Inc. (C) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs Gilead Sciences, Inc. — how do they compare? Citigroup Inc. trades at $134.3 (market cap $239.99B), while Gilead Sciences, Inc. trades at $129.81 (market cap $163.14B). The key difference: Citigroup Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.5%). Which is the better fit depends on your goals.
| C | GILD | |
|---|---|---|
Market Cap | $239.99B | $163.14B |
Sector | Financials | Health |
52-Week High | $145.67 | $155.80 |
52-Week Low | $90.02 | $108.22 |
Dividend Yield | 1.71% | 2.5% |
Enterprise Value | — | $177.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.
The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
